Tag Archives: startups

Five Leading Life Science Organisations Collaborate on Inaugural London Bio-Innovation Week 

7 Oct

By Tony Jones, CEO, One Nucleus (Special Guest Contributor)

ELRIG, Life Science Integrates, Life Science Nation, One Nucleus and SLAS will provide delegates with the opportunity for cross-event partnering during London Bio-Innovation week, which runs 1-5 December, 2025

One Nucleus’ Genesis conference partnering app open to delegates attending any of Bio-Innovation Week events

Initiative to provide extended opportunities for networking, to support the life science ecosystem


London, UK, 30 September 2025: ELRIG, Life Science Integrates, Life Science Nation, One Nucleus and The Society for Laboratory Automation and Screening (SLAS) today announced that they will be collaborating during London Bio-Innovation week, to facilitate multi-event networking and partnering opportunities for life science companies.

London Bio-Innovation week, which runs 1-5 December, 2025, will see each of the five organisations delivering events in the UK’s capital city. While each event is being run independently, collectively their co-location in one city provides a unique opportunity to meet with in excess of 1000 of the brightest science and business minds in London that week.

To further support those seeking new collaborations, insights and opportunities, the event organisers will provide the opportunity for cross-event partnering. Delegates attending any one of the Bio-Innovation Week events will be able to access the One Nucleus Genesis app, to connect with delegates attending different conferences.

Tony Jones, CEO, One Nucleus, said: “Collaboration sits at the core of translating world leading bioscience research into new ventures developing innovative products and technologies to improve patient outcomes. With so much activity in London for Bio-Innovation Week, we identified a unique opportunity to support the life science sector, by opening the Genesis conference partnering app to both attendees and non-attendees, providing a platform for partnering across the multiple events.”

London Bio-Innovation Week Events:

About ELRIG https://elrig.org/

ELRIG are proud to be a leading European not-for-profit organisation dedicated to uplifting the life science and drug discovery community. Our mission is to foster open access to modern research and innovation. Bringing together our vibrant community of over 12,000 life science professionals from academia and biopharma to connect, collaborate and encourage curiosity.

Contact: Sanj Kumar, CEO sanj.kumar@elrig.org

About Life Science Integrates https://lifescienceintegrates.com/

Formed in 2011 by Christopher Watt and Samuel Thangiah, Life Science Integrates (LSI) brings together Senior Leaders from across the Life Sciences, including industry, academia, government and regulators; providing them with unique opportunities to be part of the conversations that set out the industry’s challenges and identify effective strategies and solutions.

Contact: Samuel Thangiah, Founder and Executive Director samuel.thangiah@lsi-uk.com

About Life Science Nation (RESI) https://www.lifesciencenation.com/

The Redefining Every Stage of Investment (RESI) conference series, provided by Life Science Nation, connects start-ups and investors and strategic licensing partners. RESI maximizes fundraising companies’ efforts to find partners who are a fit for their technology and stage of development. RESI is uniquely cross-border and cross-domain, connecting start-ups with 10 categories of global investors across the silos of drugs, devices, diagnostics and digital health. RESI caters to both the earliest stage start-ups, those seeking grants, seed and angel capital, and the early-stage firms who seek series A and B funding. RESI is a unique and powerful tool for sourcing assets and advancing innovation across early-stage life science and healthcare.

Contact: Greg Manix VP International Business Development g.mannix@lifesciencenation.com

About One Nucleus https://onenucleus.com/

One Nucleus is a not-for-profit Life Sciences & Healthcare membership organisation headquartered in Cambridge. We support institutions, companies and individuals in the Life Sciences sector providing local, UK-wide and international connectivity.

Contact: Tony Jones, CEO tony@onenucleus.com

About SLAS https://www.slas.org/

The Society for Laboratory Automation and Screening is the global leader in bringing life sciences researchers and laboratory technology providers together under one roof for knowledge sharing and collaboration aimed at transforming research. Annually, SLAS holds its must-attend International Conference & Exhibition in the U.S. and its Europe Conference and Exhibition, with opportunities for start-ups to gain exposure to thousands of potential customers, as well as award opportunities for scientific content by way of poster presentations and the annual Innovation Award. Regular networking events around the world enable regional communities to come together to strengthen research collaboration.

Contact: Vicki Loise, CEO vloise@slas.org or SLAS Europe Ambassador, Manuela Beil-Peter, mbeilpeter@slas.org

Media Contact Information :

Media contact

Lorna Cuddon
Zyme Communications
Tel: +44(0)7811 996 942
Email: lorna.cuddon@zymecommunications.com

Tony Jones, One Nucleus
email: tony@onenucleus.com

Register for RESI London Register for RESI & Genesis Combi Ticket

 

Tags: , , , , , , , , ,

How 100% Pharma Tariffs Could Ripple Through Early-Stage Biotech Investment 

7 Oct

By Sougato Das, President and COO, LSN

Sougato-Das

We have all heard about the recent 100% pharma tariff announcement, applicable mainly to manufacturers or marketed drugs unless they are in the process of building manufacturing facilities in the US. We know that early stage biotechs are generally not counting on investment to take them through manufacturing, for which they will seek a pharma partner. Nevertheless, these tariffs may still have an effect on early-stage biotech investments. Investment in early-stage (seed, Series A/B) biotech is likely to face increased headwinds under a 100 % pharmaceutical tariff regime. The tariff risk exacerbates existing structural challenges in biotech investing.

Overall Expected Effect (Short to Medium Term) 

  • Slower fundraising pace 
    The number of deals may decline, particularly in the earlier stages. Biotech investors will likely become more selective, preferring de-risked assets, strong data, or compelling platforms with clear strategies to mitigate tariff exposure.
  • Higher effective cost of capital 
    Investors will demand more upside or stricter protections (e.g. liquidation preferences, anti-dilution) to compensate for the added risk.
  • Greater emphasis on capital efficiency / leaner burn models 
    Startups may need to conserve cash more, focus earlier on key inflection points, outsource less, and plan fallback strategies for supply chain risk.
  • Longer timelines / delayed exits 
    Because of the risk, uncertainty, and possible delays, the time to IPO, acquisition, or commercialization may stretch, further compressing IRR for investors.
  • Capital flow shift toward infrastructure and enabling technologies 
    Some portion of venture capital may redirect toward bioprocessing, domestic manufacturing, synthetic biology for local API production, supply-chain tools — companies that can help others evade tariff impact.
  • Public market investment in pharma may slow, leading to less IPOs 
    The tariffs could serve to further erode the attractiveness of the biopharma sector for public market investors, reducing the room for IPOs, and pressuring investment taking place more upstream.

In summary, while the recent 100% pharma tariffs certainly don’t have a direct effect on early-stage biotech investing, their dampening effects will nonetheless be felt.

Tags: , , , , , , , , , , , , , , , , ,

Super Early Bird Rates End October 3 for RESI London and RESI JPM 

30 Sep

By Sougato Das, President and COO, LSN

Sougato-Das

Life Science Nation’s Redefining Every Stage of Investments (RESI) conferences are designed to connect life science companies with global investors and strategic partners. Two major upcoming events, RESI London and RESI JPM, are now open for registration at Super Early Bird rates through October 3. By registering early, attendees can save £300 on RESI London and $800 on RESI JPM.

RESI London 2025

The first week of December marks the largest life science partnering and venture week in the UK. If you are raising pre-seed, seed, round A or round B, or are in phase 2 or earlier development, Life Science Nation’s RESI London, One Nucleus’ Genesis, and ELRIG/SLAS events offer stronger partnering, investment, learning, and procurement opportunities compared to the health care week in late November that runs alongside the Jefferies investment banking event. That November week typically focuses on recent IPOs, companies close to IPO, and phase 3 or more advanced companies seeking partnerships. For companies not yet at that stage, December’s conference series is a more strategic use of critical conference and travel budgets.

RESI London and Genesis are joining to provide a multi-day investment, partnering, and thought leadership event for venture-stage companies pursuing funding and strategic alliances. RESI London will take place on December 4 at 1 Wimpole Street and 11 Cavendish Square, followed by two days of virtual partnering on December 5 and 6. Super Early Bird registration is now open, offering a savings of £300 until October 3.

RESI JPM 2026

RESI JPM will be held January 12–13, 2026, at the San Francisco Marriott Marquis. The program features two days of in-person investor panels, workshops, networking, and one-on-one partnering, followed by three days of online partnering on January 14, 19, and 20.

Previous RESI JPM conferences have drawn more than one thousand attendees, including over 500 investors, innovators, and industry experts from across the globe. The conference is held concurrently with JP Morgan Healthcare Week, January 12–15, 2026, which takes place at the Westin St. Francis. Known as the largest healthcare investment symposium worldwide, JPM attracts thousands of life science professionals each year.

Super Early Bird registration for RESI JPM offers a savings of $800 when completed before October 3.

Register for RESI London
Register for RESI & Genesis Combi Ticket		 Register for RESI JPM

Both conferences provide access to global investors and in-licensors, strategic partners, and hundreds of early-stage innovators across therapeutics, medical devices, diagnostics, and digital health. Register now to take advantage of Super Early Bird discounts for RESI London and RESI JPM before October 3.

Tags: , , , , , , , , , , , , , , , ,

Investor Panels at RESI JPM 2026 

30 Sep

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Life Science Nation (LSN) is excited to announce the lineup of investor panels at RESI JPM 2026, taking place January 12–13. These panels bring together leading venture capitalists, corporate investors, and strategic partners to discuss the latest trends, challenges, and opportunities in life science investing. From early-stage “first check” VCs to specialized sectors like Cell & Gene Therapy, AI in Healthcare, and Longevity, RESI JPM offers unparalleled insight into the funding landscape. 

Day 1 – January 12 

  • 9:00 AM | “First Check” VCs Panel: Learn how early-stage investors evaluate founders, milestones, and the critical first institutional check. 
  • 10:00 AM | Medtech Strategics Panel: Explore how strategic investors from leading medtech companies drive growth through partnerships and acquisitions. 
  • 11:00 AM | Asia Cross Border Investments Panel: Sponsored by Enterprise Singapore, a RESI JPM Title Sponsor
  • 1:00 PM | Family Offices Panel: Hear how family offices provide patient, mission-driven capital to early- and growth-stage companies. 
  • 2:00 PM | Cell & Gene Therapy Panel: Discover where capital is flowing in this transformative area of medicine. 
  • 3:00 PM | When Should Companies Exit Stealth Mode?: Gain insight into timing the transition from quiet development to public visibility. 
  • 4:00 PM | Aging and Longevity Panel: Learn how investors are deploying capital to solutions addressing the world’s aging population. 

Day 2 – January 13 

  • 9:00 AM | Partnering with Global Pharma Panel: Understand how big pharma approaches early-stage partnerships and collaboration. 
  • 10:00 AM | Women’s Health Panel: Explore investment opportunities in an underserved market with enormous potential. 
  • 11:00 AM | AI in Healthcare: Discover how AI is reshaping drug development and care delivery. 
  • 1:00 PM | Orphan & Rare Diseases Panel: Learn about unique challenges and opportunities in niche, high-need markets. 
  • 2:00 PM | Corporate VC Panel: Hear how corporate venture capital balances strategic and financial goals to accelerate innovation. 
  • 3:00 PM | Techbio & Synthetic Biology Panel: Explore investment trends at the intersection of biology and technology. 
  • 4:00 PM | 2026 Outlook: VC Perspectives Panel: Gain insight into where investors see healthcare innovation heading in the coming year. 

These panels are designed not only to share insights but also to foster dialogue between investors and innovators. If you are interested in speaking on a RESI JPM investor panel, please reach out here. 

Registration for RESI JPM 2026 is now open, with Early Bird rates available until October 24. Don’t miss your chance to connect with top investors, strategic partners, and fellow innovators at one of the premier life science partnering events. Register for RESI JPM 2026 

Register for RESI JPM >>

Tags: , , , , , , , , , ,

LSN Staff on Global Event Circuit; Find Out Who, What, and Where

30 Sep

By Max Braht, Director of Business Development, LSN

Max-Braht-Headshot

Life Science Nation is on the move. Between now and RESI London, our team will be attending a series of leading life science and medtech conferences around the world, connecting with innovators, investors, and strategic partners. Getting out into the global ecosystem allows us to better understand emerging trends, foster collaborations, and support life science companies in reaching their fundraising and partnership goals.

These engagements also reinforce the value of our global conference, RESI, which brings together investors, entrepreneurs, and strategic partners from across the world to drive innovation in life sciences. Attending regional and international events helps us strengthen these connections and grow our global community.

Here’s where you can find our team in the coming months:

October 
Oct. 4–8: San Diego for the MedTech conference, engaging with medical device innovators and investors. San Diego, CA
  • Max Braht (m.braht@lifesciencenation.com)
  • Matt Stanton (m.stanton@lifesciencenation.com)
Oct. 4–8: LSN Bootcamp and BioSpain, connecting with early-stage life science companies. Barcelona, Spain
  • Greg Mannix (g.mannix@lifesciencenation.com)
  • Karen Deyo (k.deyo@lifesciencenation.com)
  • Brenda Olmos (b.olmos@lifesciencenation.com)
Oct. 8–10: Japan for BioJapan, focusing on international biotech partnerships. Yokohama, Japan
  • Dennis Ford (dford@lifesciencenation.com)
  • Claire Jeong (c.jeong@lifesciencenation.com)
  • Momo Yamamoto (m.yamamoto@lifesciencenation.com)
Oct. 21-23: Sao Paulo for Corporate Venture in Brazil 2025, highlighting innovation and investment opportunities in Latin America. Sao Paulo, Brazil
  • Dennis Ford (dford@lifesciencenation.com)
  • Max Braht (m.braht@lifesciencenation.com)
  • Matt Stanton (m.stanton@lifesciencenation.com)
Oct 24-25: Washington DC for the 9th Annual KAPAL Conference, meeting global leaders in biotech and healthcare. Washington DC
  • Sougato Das (s.das@lifesciencenation.com)
Oct. 27–28: Miami for the BioHunt Summit, meeting emerging life science startups and investors. Miami, FL
  • Dennis Ford (dford@lifesciencenation.com)
  • Matt Stanton (m.stanton@lifesciencenation.com)
November 
Nov. 2–6: Vienna for BioEurope, connecting with corporate and venture partners across the life science ecosystem. Vienna, Austria
  • Max Braht (m.braht@lifesciencenation.com)
  • Greg Mannix (g.mannix@lifesciencenation.com)
Nov. 12–14: Malta at the MedTech World Summit, exploring opportunities in medical technology. Valletta, Malta
  • Greg Mannix (g.mannix@lifesciencenation.com)
  • Brenda Olmos (b.olmos@lifesciencenation.com)
Nov. 16–20: London for Jefferies London Life Sciences Week, engaging with global investors and biotech innovators. London, UK
  • Max Braht (m.braht@lifesciencenation.com)
  • Greg Mannix (g.mannix@lifesciencenation.com)
December 
Dec. 2: France for Biofit/Medfit, meeting early-stage innovators and strategic partners in biotech and medtech. Strasbourg, France
  • Max Braht (m.braht@lifesciencenation.com)
  • Matt Stanton (m.stanton@lifesciencenation.com)

We look forward to seeing our community at these events. If you’d like to connect with us while we’re on the road, please reach out to resi@lifesciencenation.com

Tags: , , , , , , , , , , , ,

Life Science Nation and The Ganesha Lab Launch a Global Two-Way Innovation Bridge Connecting South America, Anchored in São Paulo, Brazil, to the International Healthcare Arena 

23 Sep

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

DF-News-09142022São Paulo, Brazil – September 23, 2025 – In a landmark move to expand Latin America’s role in the global life sciences sector, Life Science Nation (LSN) and The Ganesha Lab (TGL), Latin America’s premier life sciences scale-up platform, announce a strategic alliance to launch a dedicated bricks-and-mortar accelerator hub in São Paulo by the end of 2025.

Uniting Global Scale with Local Depth

The São Paulo-based facility will serve as the Latin American anchor node of LSN’s global partnering backbone, a system of affiliated tech hubs, economic development agencies, incubators, and accelerators worldwide, all connected through LSN’s two-way innovation bridge model.

This new effort builds upon years of development work with leading Brazilian stakeholders, including Abiquifi and ApexBrasil, alongside local governments, universities, and innovation agencies, as well as service providers, to ensure the hub will be fully integrated into Brazil’s national strategy for life sciences by both LSN and TGL.

  • The Ganesha Lab brings regional depth: through its BigInBIO scale-up platform, TGL sources and mentors startups, delivers structured readiness programs, builds an alumni base across Latin America, and maintains strong relationships with CROs, universities, governments, and pharma partners. As LSN’s anchor partner for Latin America, TGL provides the credibility and local integration that enable the bridge to function.
  • Life Science Nation brings global reach: as the architect of the two-way innovation bridge, LSN provides a commercialization-first partnering backbone that includes its curated 4,000-profile investor and licensing partner database, AI-driven readiness assessments, BD Assist outbound campaign execution, and the five annual RESI investor conferences worldwide, where more than 400 companies have raised over $5B.

Tangible, Two-Way Impact

  • Outbound: Building on TGL’s BigInBIO platform, Latin American startups will be mentored and readied regionally, then advanced into LSN Labs’ commercialization-first global roadshow process, narrative refinement, global target list creation, CRM-driven outreach, and full integration into international RESI conferences.
  • Inbound: Global life sciences technologies, investors, and licensing partners will be brought into Brazil through LSN’s ecosystem, leveraging TGL’s local networks to accelerate collaboration, validation, and market entry.
  • Capital & Partnering Alliances: International investors and licensing partners from LSN’s global network will syndicate with Brazilian VCs, corporates, and pharma, expanding capital access and helping local partners build a global footprint.

Together, TGL and LSN create a seamless pathway: from regional readiness → to global campaign execution → to inbound technologies and capital integrating into Latin America. The São Paulo accelerator will serve as the anchor node for Latin America in LSN’s global partnering backbone.

Accelerator Operations and Ecosystem Collaborations

A newly formed Brazilian team will operate the São Paulo accelerator, working with new and existing partners from local government, top universities, regional innovation agencies, and service providers. The accelerator will act as a permanent node, building local capacity while embedding Latin America into the global life sciences economy.

“We are committed to powering innovation in both directions, helping Latin American startups scale globally and enabling global innovators to leverage Brazil’s unique advantages,” said Dennis Ford, Founder & CEO of Life Science Nation.

“Together, we are creating an innovation bridge that not only builds businesses but also strengthens Brazil’s role as the leading gateway for life sciences innovation in Latin America,” said Markus Schreyer, Founder & CEO of The Ganesha Lab.

“LSN has built a precision matching and meeting connection engine for over a decade, helping more than 400 companies raise $5B. Anchoring the accelerator in Brazil will strengthen the LATAM market and connect the region directly into LSN’s global backbone. The time is right to bring Latin America into the network and expand its global life science footprint,”  said Matt Stanton, LSN’s VP of LATAM Business Development.

The program is targeting going live by the end of 2025 or early 2026. The São Paulo hub will be the first of its kind in Latin America, with the potential to replicate across other innovation centers in the region, further embedding Latin America into the global life sciences economy.

The partnership will also be highlighted at the upcoming BioHunt Summit 2025 in Miami, where Dennis Ford and Markus Schreyer will hold a fireside chat to expand on the announcement.

About Life Science Nation (LSN)

Life Science Nation (LSN), founded by Dennis Ford, is a global leader in connecting early-stage life science companies with capital investors and licensing partners. LSN owns and operates the LSN Investor & Licensing Partner Database (4,000 curated profiles), the Redefining Early-Stage Investments (RESI) Conference Series (five global partnering events annually), and the LSN Newsletter (60,000 global readers), alongside podcasts and published works such as The Life Science Executive’s Fundraising Manifesto.

Through its accelerator arm, LSN Labs, LSN has pioneered the two-way innovation bridge model, a partnering backbone that affiliates with tech hubs, incubators, accelerators, and economic development agencies worldwide. This model enables regions, patient groups, and nonprofits to aggregate technology assets, launch them outbound into global markets, and simultaneously bring inbound capital, licensing partners, and technologies into their ecosystems. Over the past decade, LSN has helped more than 400 companies raise over $5 billion through global roadshow campaigns and partnering events.

About The Ganesha Lab (TGL)

The Ganesha Lab (TGL), founded by Markus Schreyer, is Latin America’s premier life sciences scale-up platform. Through its flagship program BigInBIO, TGL provides structured readiness programs, mentoring, and founder development for biotech and health startups. Selected companies may also receive investment support, with TGL maintaining long-term engagement for three years or more post-program through its alumni network.

With strong ties to CROs, universities, governments, and pharma across the region, TGL plays a vital role in sourcing and nurturing the most promising science-based ventures in Latin America, preparing them for international scale-up and investment. TGL’s proven regional expertise and credibility make it the ideal anchor partner for launching the São Paulo accelerator and establishing Latin America as a key node in the global life sciences economy.

Tags: , , , , , , , , , ,

RESI Boston September 2025 Innovator’s Pitch Challenge Winners 

23 Sep

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

At RESI Boston September 2025, over 50 innovative companies participated in the Innovator’s Pitch Challenge (IPC), providing early-stage life science and healthcare companies with a unique platform to present their technologies and connect with potential investors.

The IPC finalists delivered 6-minute pitches followed by a 7-minute interactive Q&A session with a panel of investor judges. Each participating company also showcased its technology at a personalized table space in the RESI Exhibition Hall, creating additional opportunities for engagement.

A distinctive feature of the Innovator’s Pitch Challenge is its voting system. Registered RESI attendees—including startup executives, early-stage investors, and industry experts— “invested” in their favorite IPC companies using RESI cash provided at check-in. Attendees base their decisions on both the pitch presentations, the companies’ responses during Q&A, meeting with them in the exhibition hall at their table space, and during partnering or ad-hoc meetings at RESI.

Applications are now open for the next Innovator’s Pitch Challenge at RESI London 2025 and RESI JPM 2026, with spots filled on a rolling basis.

Life Science Nation is proud to announce the top three winners of RESI Boston September 2025:

1st Place: Isotech

IsoTech Ltd is developing a novel wearable therapeutic medical device that stabilises blood pressure on standing to help older adults avoid dizziness and falls from orthostatic hypotension. The device guides a 30–60-second, on-demand isometric muscle contraction via a discreet retractable tether with visual and haptic cues, turning an evidence-based counter-manoeuvre into a simple, repeatable action without drug side effects. A completed proof-of-concept clinical study demonstrated clinically meaningful blood-pressure stabilisation in a substantial subset of patients with high usability and no unwanted adverse effects. The next phase is straightforward but execution-critical: design-for-manufacture and verification, Class I UKCA/CE technical documentation and light-touch QMS, tooling and pilot build, and a KOL-led seeded launch while preparing reimbursement pilots and strategic licensing options. Protected by patents on mechanism and form factor, ISO-101 aims to become the category-defining, real-time therapy for OH, improving independence for ageing populations and reducing falls-related costs for health systems at scale.

Dr Lochlainn Connolly, Founder – EVP Medical Affairs, Isotech | Dr Neil Fawkes, Founder / EVP R&D, Isotech | Dennis Ford, Founder and CEO, Life Science Nation | Iggy McGowan, Founder / CEO, Isotech

2nd Place: BILIX

Bilix, founded in Oct 2018, raised $21 million in investments and received $3 million in government grants to develop a new drug for various inflammatory and autoimmune diseases. Our first target is ischemia-reperfusion injury, where unmet medical needs are high and no drugs. Global companies (Novartis, Roche, AstraZeneca, Argenx) are in Phase 2 or 3 trials with single-modality drugs (likely to fail). Our Phase 2a clinical trial (our drug being multi-modality, likely to succeed) runs from 2025.09 to 2026.08. We generate royalty revenue from Classys (a $3B market cap laser medical device company) through exclusive LO in cosmeceutical products. We are currently raising Series B-3 of $6M, of which $ 3 M has been secured. With $25.7 million pre-money valuation, an ROI of >10 times is achievable within three years through IPO/M&A. We can flip to a US company with vetted Series C investments from US/Foreign VCs.

Dennis Ford, Founder and CEO, Life Science Nation | Myung L. Kim, Ph.D., MBA, Founder and Chief Executive Officer, Bilix | Claire Jeong, CCO, VP of Investor Research, Asia BD, Life Science Nation

3rd Place: M6P Therapeutics

M6P Therapeutics focuses on lysosomes (the natural recycling center for cells) and has the only technology that can deliver any protein to lysosomes – a feat deemed impossible for over 50 years. The company has a deep pipeline, 6 rare pediatric drug designations, and an IP portfolio comprised of 9 patent families, 8 issued patents, and 20 in progress. Our Gaucher Disease ERT is ready for the clinic and our Pompe Disease ERT – which can restore and normalize muscle function – will be ready in 18 months. We also created a platform that can take any antigen-antibody complex to the lysosomes of any cell in the body (instead of relying on Fc clearance by select immune cells) for degradation. Our “chimeric” anti-PD-L1 antibody removes virtually all PD-L1 from the surface of tumor cells while our chimeric version of Keytruda is twice as potent.

Cole Van Vuren, Business Development Manager, Life Science Nation

The participating companies were grouped into 14 sector-focused sessions, with four companies per session. Each session was evaluated by a panel of judges, and the top-scoring companies were recognized for their strong pitches, ability to answer questions effectively, and clear communication of their value propositions.

Judges Picks:

Tags: , , , , , , , , , ,

← Older Entries
Newer Entries →